Technopolis Moscow SEZ will start producing a Russian drug for the treatment of melanoma

11.10.2026

Technopolis Moscow SEZ will start producing a Russian drug for the treatment of melanoma
Technopolis Moscow SEZ will start producing a Russian drug for the treatment of melanoma
Technopolis Moscow SEZ will start producing a Russian drug for the treatment of melanoma
Technopolis Moscow SEZ will start producing a Russian drug for the treatment of melanoma

The pharmaceutical plant in the Technopolis Moscow Special Economic Zone (SEZ) will launch the production of an innovative Russian drug for the treatment of melanoma. The company began to transfer the production of the finished dosage form to the site. This was announced by Maxim Liksutov, Deputy Mayor of Moscow for Transport and Industry.

"On behalf of Moscow Mayor Sergei Sobyanin, the city is developing pharmaceuticals as one of the key branches of the capital's industry. The resident of the special economic zone produces a number of unique drugs on the site, including the first original Russian medicine for multiple sclerosis. Since 2021, the company has produced more than 8.5 million packages of medicines for the treatment of oncological and autoimmune diseases," said Maxim Liksutov.

The Biocad company is engaged in the production of the original Nurdati drug for the treatment of melanoma. Its PK-137 production complex is located on the site of the capital's SEZ and is part of the country's largest pharmaceutical cluster.

The innovative drug combines two monoclonal antibodies, nurulimab and prolgolimab. They act on CTLA-4 and PD-1 receptors and help the immune system recognize and destroy tumor cells. The drug is prescribed to patients whose tumor cannot be surgically removed or has already metastasized.

To begin production, the company's specialists will transfer and adapt technological processes, conduct validation and go through regulatory procedures. Production in the city will shorten the path of the drug to the capital's medical organizations, and Moscow patients will be able to receive the necessary therapy faster.

"The creation of an original drug does not end with its registration and market entry. An important part of its life cycle is to meet the needs of the healthcare system. The transfer of medicines to the SEZ site meets the goals and objectives of the Moscow Government in the field of localization of drug production and is part of the company's systematic work," said Alexey Torgov, Deputy General Director for Corporate Relations and Communications at Biocad.

The company's production complex in the Technopolis Moscow SEZ occupies 43 thousand square meters. In 2022, a site for liquid dosage forms was opened here, and in 2024, the production of divozilimab, a drug for the treatment of multiple sclerosis, was mastered.

Technopolis Moscow Special Economic Zone celebrates its 20th anniversary in 2026. Over two decades, the project has transformed from a launching pad for innovative projects into a key hub for the domestic industry and a center of attraction for companies that determine Russia's technological sovereignty. Today, the production of more than 250 high-tech enterprises representing such strategic areas as microelectronics, instrumentation, biomedicine, IT and robotics is localized at 10 sites of the Technopolis Moscow SEZ with a total area of 430 hectares. The capital's Department of Investment and Industrial Policy is engaged in the development of the Technopolis Moscow special economic zone.

Moscow is actively developing industrial infrastructure for high-tech enterprises. Thanks to urban solutions, companies are increasing production and launching innovative productions. This contributes to the implementation of the national project "Efficient and Competitive Economy".

Press Service of Technopolis Moscow SEZ

+7 495 647 08 18 (ext. 1209) pr@technomoscow.ru

Follow Technopolis Moscow SEZ on social media, stay updated with the main SEZ news on our Telegram channel, and receive all important updates directly to your inbox via our weekly newsletter.

Back to list

CAPTCHA
By clicking the “Send” button, you consent to the processing of your personal data in accordance with Article 9 of the Federal Law of July 27, 2006 No.152-FZ “On Personal Data”
Успех Успех

Your application has been successfully sent!